Stock TitanMAR 32 min read$INGN

[Form 4] Inogen Inc Insider Trading Activity

Inogen Inc's VP and Chief Accounting Officer, Mary E. Wright, reported several equity compensation transactions detailed in a recent Form 4 SEC filing. These included the exercise or conversion of restricted stock units into common stock, grants of common stock, and shares withheld for tax liabilities. A new grant of 8,000 restricted stock units was also awarded, vesting over several years.

Original reporting

Stock Titan

Published Mar 3, 2026, 9:59 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Mar 3, 2026, 11:01 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefFinancial news

Primary signal

$INGN

Neutral

medium confidence

Mentioned

$INGN

AlphAI data visualization · based on Stock Titan

Decision brief

The 30-second read

$INGNNeutralLow

Why it matters

These transactions are typical compensation activities and do not necessarily reflect changes in company valuation or prospects.

Market read

While insider transactions are noteworthy, they currently do not suggest significant market-moving information for Inogen Inc.

What to watch

Insider transactions may be routine and not indicative of future performance; consider broader market and company fundamentals.

Timing: short-term

Background

Inogen Inc's VP and Chief Accounting Officer, Mary E. Wright, reported several equity transactions in a recent SEC Form 4 filing, including stock exercises and grants.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$INGNNeutralMedium confidence

Context

Insider trading activity involving equity compensation transactions by company executives.

Expected impact

Minimal short-term price movement expected; long-term impact uncertain.

Evidence & confidence

Insider transactions are common and may reflect compensation strategies rather than market signals. The neutral sentiment and typical transaction types support a cautious outlook.

Market effects

Sector

Limited; insider activity does not significantly alter sector outlook.

Regional

Negligible; no regional effects anticipated.

Global

Negligible; specific to Inogen Inc with no broader global implications.

Counterpoint

What could challenge this read

Insider buying could indicate management's confidence in future growth, potentially signaling a positive outlook.

Key entities

Person
Mary E. Wright
VP and Chief Accounting Officer of Inogen Inc.
Company
Inogen Inc
A provider of portable oxygen concentrators and related respiratory products.

Read at source ← All news

AUG 17

$INGNMedAI 8/10

Inogen (INGN) Cuts Guidance Even As Profitability Climbs

Inogen (NASDAQ:INGN) reported Q2 results with improving profitability and continued international growth, but weakness in the US oxygen rental and direct-to-consumer channels. International revenue was $41.3M (+15% YoY). US sales fell 2% to $42.3M and rental revenue dropped 12% to $11.6M. Full-year 2026 revenue guidance was cut to $355M-$361M.

insidermonkey.com6 min

AUG 14

$INGNMedAI 9/10

Inogen (INGN) Q2 2026 Earnings Call Transcript

Inogen (INGN) reported Q2 2026 revenue of $95.1 million, up 3% year over year, driven by international sales of $41.3 million (+14.8%) and new product contributions. U.S. sales were $42.3 million, down 2.3%. Adjusted EBITDA was $2.4 million (+15.2%). Full-year revenue guidance was cut to $355-$361 million; adjusted EBITDA guidance is about $4 million. Cash was $106.8 million with zero debt.

fool.com6 min

AUG 11

$INGNMedAI 8/10

Inogen Cuts 2026 Revenue Outlook as U.S. Channel Pressure Persists

Inogen (INGN) cut its 2026 revenue outlook to $355 million to $361 million from $366 million to $373 million after Q2 results showed ongoing U.S. channel pressure. Q2 U.S. sales fell 2.3% to $42.3M and U.S. rentals fell 11.8% to $11.6M, while international revenue rose 14.8% to $41.3M. Adjusted gross margin rose to 45.6%.

tradingview.com4 min

AUG 6

$INGNHigh

Inogen Announces Second Quarter 2026 Financial Results

Inogen Inc (INGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Inogen Announces Second Quarter 2026 Financial Results Reported second quarter revenue of $95.1 million Company raises full-year adjusted EBITDA guidance to approximately $4.0 million BEVERLY, Mass., August 6, 2026 -- Inogen, Inc. (Nasdaq: INGN ), a medical technolog

SEC EDGAR 8-K4 min

SEP 30

$LLYMedAI 8/10

Retatrutide Yields Significant Weight Loss in T2D

Eli Lilly's phase 3 TRIUMPH-2 study shows retatrutide, a triple hormonal agonist, achieved significant weight loss (up to 20.8%) and glycemic improvements in adults with type 2 diabetes (T2D) and obesity. The study, presented at EASD 2026, involved 1152 participants and showed retatrutide's efficacy estimand exceeded 20% weight reduction, a threshold not previously reached in T2D patients.

medscape.com3 min